New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
07:33 EDTPOZN, GSK, PTXPernix Therapeutics to make $3M payment to CPPIB Credit Investments
In connection with the assignment of the PDC Agreement, Pernix (PTX) shall make a payment of $3M to CPPIB Credit Investments Inc. and has also granted POZEN (POZN) a warrant to purchase 500,000 shares of Pernix common stock at an exercise price equal to the closing market price on May 13, 2014. The warrants will be exercisable from the closing date of the transaction until February 2018. The amended PDC Agreement provides for royalties of 18% of net sales with quarterly minimum royalty amounts of $4M for the calendar quarters commencing on January 1, 2015 and ending on March 31, 2018.
News For PTX;GSK;POZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
11:16 EDTGSKAdaptimmune initiates Phase I/II trial of affinity enhanced T-cell therapy
Subscribe for More Information
November 23, 2015
09:07 EDTPOZNPOZEN, Tribute provide update on pending combination
POZEN and Tribute Pharmaceuticals Canada provided an update on their pending combination transactions. The companies have reviewed the recent guidance from the U.S. Treasury's Notice 2015-79 issued on November 19 and its potential impact on the proposed transaction. POZEN and Tribute remain committed to combining their respective businesses and are considering a Canadian domicile for Aralez Pharmaceuticals, the new parent entity for the combined companies. With the planned business operations in Ireland, Canada and the United States, the Canadian domicile offers substantially similar financial, tax and competitive advantages to an Irish domicile, and will benefit from Tribute's business foundation and strong presence in Canada where Tribute was incorporated and from where it has always operated. The parties further believe that a Canadian domicile will be in compliance with the new Treasury Department Guidance and are working diligently and expeditiously on an alternative transaction structure that would be in the best interest of their respective securityholders, and the parties are further considering the Treasury Department Guidance as they continue to arrive at this alternative transaction structure.
08:08 EDTGSKIdera Pharmaceuticals announces partnership with GSK
Idera Pharmaceuticals (IDRA) announced it has entered into an exclusive worldwide collaboration and license agreement with GSK (GSK) to research, develop and commercialize selected molecules from Idera's 3rd generation antisense platform for the treatment of selected targets in renal disease. Under the terms of the agreement, Idera is eligible to receive approximately $100M in development and regulatory milestone payments, including a $2.5M upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500M.
November 19, 2015
10:11 EDTPOZNHigh option volume stocks
November 18, 2015
08:11 EDTGSKIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
November 16, 2015
07:22 EDTPTXBrean Capital to hold a summit
Subscribe for More Information
November 12, 2015
11:17 EDTPTXPernix Therapeutics says study shows silenor superior to zolpidem
Pernix Therapeutics announced interim results from a Phase IV study assessing the effects of a nighttime administration of Silenor 6 mg, zolpidem 10 mg, and placebo on arousability, gait/balance, and cognitive performance in healthy volunteers. The study assessed the effects of a single dose of Silenor 6 mg compared with matching placebo and a single dose of zolpidem 10 mg compared to its matching placebo at the respective Tmax in normal healthy adult male volunteers. The interim results of this head-to-head comparison demonstrate that Silenor 6 mg is statistically significantly superior to zolpidem 10 mg on all measures analyzed, the company said. The results also indicate that subjects taking Silenor 6 mg did not have impairment on any of these measures and were comparable to placebo. Further, Silenor 6 mg and both placebo groups were superior to zolpidem on all measures, indicating that zolpidem subjects had significant difficulty waking up, difficulty in their ability to walk, difficulty with balance, and experienced memory impairment.
November 11, 2015
10:03 EDTPOZNHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use